- Home
- FORR vs IMAB Comparison
FORR vs IMAB Comparison
Compare FORR & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- IMAB
- Stock Information
- Founded
- FORR 1983
- IMAB 2014
- Country
- FORR United States
- IMAB United States
- Employees
- FORR N/A
- IMAB N/A
- Industry
- FORR Diversified Commercial Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- IMAB Health Care
- Exchange
- FORR Nasdaq
- IMAB Nasdaq
- Market Cap
- FORR 193.5M
- IMAB 200.9M
- IPO Year
- FORR 1996
- IMAB 2020
- Fundamental
- Price
- FORR $9.75
- IMAB $2.13
- Analyst Decision
- FORR
- IMAB Strong Buy
- Analyst Count
- FORR 0
- IMAB 3
- Target Price
- FORR N/A
- IMAB $6.33
- AVG Volume (30 Days)
- FORR 68.4K
- IMAB 589.5K
- Earning Date
- FORR 07-29-2025
- IMAB 05-15-2025
- Dividend Yield
- FORR N/A
- IMAB N/A
- EPS Growth
- FORR N/A
- IMAB N/A
- EPS
- FORR N/A
- IMAB N/A
- Revenue
- FORR $422,269,000.00
- IMAB N/A
- Revenue This Year
- FORR N/A
- IMAB N/A
- Revenue Next Year
- FORR $2.04
- IMAB N/A
- P/E Ratio
- FORR N/A
- IMAB N/A
- Revenue Growth
- FORR N/A
- IMAB N/A
- 52 Week Low
- FORR $8.50
- IMAB $0.60
- 52 Week High
- FORR $20.62
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- FORR 45.09
- IMAB 49.76
- Support Level
- FORR $9.77
- IMAB $2.06
- Resistance Level
- FORR $11.00
- IMAB $2.41
- Average True Range (ATR)
- FORR 0.39
- IMAB 0.33
- MACD
- FORR -0.01
- IMAB -0.07
- Stochastic Oscillator
- FORR 28.21
- IMAB 12.63
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).